Several studies have demonstrated that vimentin contributes to angiogenesis and the use of regulators of tumor angiogenesis (such as PARP inhibitors) leads to the reduction of vimentin expression and suppression of tumor angiogenesis in vascular endothelial cells [53,55]. This evidence concerns the gene VIM and neoplasm.